Allergan PLC (AGN) Stock Price Down 1.4%
Shares of Allergan PLC (NYSE:AGN) were down 1.4% on Thursday . The company traded as low as $238.72 and last traded at $239.83, with a volume of 2,623,369 shares. The stock had previously closed at $243.27.
A number of analysts have weighed in on AGN shares. Vetr cut shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $275.94 target price on the stock. in a report on Thursday, June 2nd. Wells Fargo & Co. reissued a “buy” rating on shares of Allergan PLC in a report on Tuesday, May 31st. Citigroup Inc. reissued a “buy” rating on shares of Allergan PLC in a report on Sunday, May 29th. Cowen and Company reissued a “buy” rating on shares of Allergan PLC in a report on Tuesday, May 24th. Finally, Goldman Sachs Group Inc. cut shares of Allergan PLC to a “buy” rating in a report on Saturday, May 14th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $309.13.
The company has a market capitalization of $94.21 billion and a price-to-earnings ratio of 22.65. The company has a 50 day moving average of $248.71 and a 200-day moving average of $248.84.
Allergan PLC (NYSE:AGN) last released its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.34 by $0.01. The business earned $3.68 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the prior year, the firm earned $4.41 earnings per share. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. On average, equities analysts anticipate that Allergan PLC will post $14.00 EPS for the current year.
In other Allergan PLC news, CFO Maria Teresa Hilado purchased 661 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The stock was acquired at an average cost of $241.57 per share, with a total value of $159,677.77. Following the completion of the acquisition, the chief financial officer now directly owns 11,957 shares of the company’s stock, valued at approximately $2,888,452.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Several hedge funds and institutional investors have added to or reduced their stakes in AGN. Eaton Vance Management boosted its position in Allergan PLC by 276.7% in the fourth quarter. Eaton Vance Management now owns 793,555 shares of the company’s stock worth $247,986,000 after buying an additional 582,890 shares in the last quarter. State of Tennessee Treasury Department boosted its position in Allergan PLC by 135.7% in the fourth quarter. State of Tennessee Treasury Department now owns 466,141 shares of the company’s stock worth $145,669,000 after buying an additional 268,357 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Allergan PLC by 6.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,596,389 shares of the company’s stock worth $498,895,000 after buying an additional 103,314 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Allergan PLC by 4.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 1,069,878 shares of the company’s stock worth $334,337,000 after buying an additional 40,665 shares in the last quarter. Finally, Rail Splitter Capital Management LLC boosted its position in Allergan PLC by 39.4% in the fourth quarter. Rail Splitter Capital Management LLC now owns 51,574 shares of the company’s stock worth $16,117,000 after buying an additional 14,565 shares in the last quarter.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.